Table 2:
Top 10 enriched FDA drug signature pathways of MS-associated gene network
| Drug name | Indication of medication | Genes contributing to drug signature pathway | Raw p-value | FDR* |
|---|---|---|---|---|
| Rubidomycin hydrochloride | Acute myeloid leukemia | HSPA1A, JAK2, MAPK1, STAT3 | 3.36 × 10−4 | 0.014 |
| Zafirlukast | Prophylaxis in asthma | KAT2A, MAPK1, MAPK3 | 4.05 × 10−4 | 0.014 |
| Podophyllotoxin | Genital warts | JAK2, STAT3, TUBB3 | 8.21 × 10−4 | 0.016 |
| Hexachlorophene | Disinfectant | KAT2A, MAPK1, MAPK3, STAT3 | 9.17 × 10−4 | 0.016 |
| Etoposide | Chemotherapy | MAPK1, MAPK3 | 3.96 ×10−3 | 0.053 |
| Mitoxantrone dihydrochloride | Acute myeloid leukemia | KAT2A, MAPK1 | 4.64 ×10−3 | 0.053 |
| Doxorubicin Hydrochloride | Acute myeloid leukemia | JAK2, MAPK1, STAT3 | 7.79 ×10−3 | 0.060 |
| Ruxolitinib phosphate | Myelofibrosis | JAK2 | 7.86 ×10−3 | 0.060 |
| Palbociclib | Breast cancer | CDK4 | 7.86 ×10−3 | 0.060 |
| Zalcitabine | HIV/AIDS | MAPK1 | 0.012 | 0.081 |
*
FDR: p-value adjusted by Benjamini-Hochberg procedure for multiple tests.